Literature DB >> 15111467

Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. Recommendation statement from the Canadian Task Force on Preventive Health Care.

B L Abramson1.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 15111467      PMCID： PMC395808          DOI： 10.1503/cmaj.1030755

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  31 in total

1.  Hormone replacement therapy and cardiovascular disease: a joint statement.

Authors:  Beth Abramson; Christine Derzko; Andre Lalonde; Robert Reid; Michele Turek; Andreas Wielgosz
Journal:  Can J Cardiol       Date:  2002-07       Impact factor: 5.223

Review 2.  Amended report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy.

Authors: 
Journal:  Menopause       Date:  2003 Jan-Feb       Impact factor: 2.953

3.  Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems.

Authors:  L E Nachtigall; R H Nachtigall; R D Nachtigall; E M Beckman
Journal:  Obstet Gynecol       Date:  1979-07       Impact factor: 7.661

4.  Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study.

Authors:  F Grodstein; J E Manson; M J Stampfer
Journal:  Ann Intern Med       Date:  2001-07-03       Impact factor: 25.391

5.  Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study.

Authors:  P W Wilson; R J Garrison; W P Castelli
Journal:  N Engl J Med       Date:  1985-10-24       Impact factor: 91.245

6.  Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community.

Authors:  M H Criqui; L Suarez; E Barrett-Connor; J McPhillips; D L Wingard; C Garland
Journal:  Am J Epidemiol       Date:  1988-09       Impact factor: 4.897

7.  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis.

Authors:  D M Herrington; D M Reboussin; K B Brosnihan; P C Sharp; S A Shumaker; T E Snyder; C D Furberg; G J Kowalchuk; T D Stuckey; W J Rogers; D H Givens; D Waters
Journal:  N Engl J Med       Date:  2000-08-24       Impact factor: 91.245

8.  Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study.

Authors:  T L Bush; E Barrett-Connor; L D Cowan; M H Criqui; R B Wallace; C M Suchindran; H A Tyroler; B M Rifkind
Journal:  Circulation       Date:  1987-06       Impact factor: 29.690

9.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

10.  Estrogen plus progestin and the risk of coronary heart disease.

Authors:  JoAnn E Manson; Judith Hsia; Karen C Johnson; Jacques E Rossouw; Annlouise R Assaf; Norman L Lasser; Maurizio Trevisan; Henry R Black; Susan R Heckbert; Robert Detrano; Ora L Strickland; Nathan D Wong; John R Crouse; Evan Stein; Mary Cushman
Journal:  N Engl J Med       Date:  2003-08-07       Impact factor: 91.245
View more
  1 in total

1.  Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care.

Authors:  C Nadine Wathen; Denice S Feig; John W Feightner; Beth L Abramson; Angela M Cheung
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.